(Reuters) - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices ...

(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order, and ...

Credit: Getty Images. Rezvoglar may now be substituted for Lantus at the pharmacy counter without the need for an intervention from the prescriber. The Food and Drug Administration (FDA) has approved ...

Initiators of biosimilar insulin glargine-yfgn were more likely to reside in rural areas, live in long-term care facilities, or have multiple prescribers and were less likely to have previously used ...